CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
Ji-Yeon Kim, Seok Jin Nam, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Jin Seok Ahn, Young-Hyuck Im, Seok Won Kim, Yeon Hee Park
Cancer Research and Treatment. 2022;54(4):1091-1098.   Published online 2022 January 10    DOI: https://doi.org/10.4143/crt.2021.901

Excel Download

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
Cancer Research and Treatment. 2022;54(4):1091-1098   Crossref logo
Link1 Link2 Link3

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
Breast Cancer Research and Treatment. 2020;184(2):481-489   Crossref logo
Link1 Link2 Link3

Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP)
Targeted Oncology. 2022;17(2):167-175   Crossref logo
Link1 Link2 Link3

Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP): Single center experience
Annals of Oncology. 2018;29:ix10   Crossref logo
Link1 Link2 Link3

Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland
Cancers. 2022;14(5):1218   Crossref logo
Link1

Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain
Value in Health. 2016;19(7):A740   Crossref logo
Link1 Link2

Economic Evaluation of Pertuzumab In Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment of Women with HER2-Positive, Locally Advanced, Inflammatory or Early Breast Cancer in Portugal
Value in Health. 2016;19(7):A736-A737   Crossref logo
Link1 Link2

Invited commentary on “Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline-free chemotherapy regimen in patients with HER2 positive breast cancer: Real-world data from a single center in India”.
Cancer Treatment and Research Communications. 2021;29:100487   Crossref logo
Link1 Link2

A Retrospective Audit on Outcomes Following Implementation of Neoadjuvant Treatment of HER2-positive Breast Cancer with Combined Pertuzumab and Trastuzumab with Docetaxel
Clinical Oncology. 2019;31(7):e111   Crossref logo
Link1 Link2

1225 Potential long-term cost savings due to significant clinical benefit of pertuzumab in combination with trastuzumab for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer
European Journal of Cancer. 2015;51:S180-S181   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.